Antibodies | Top 10 Cited Papers in 2024

1. “Diagnosis and Management of Catastrophic Antiphospholipid Syndrome and the Potential Impact of the 2023 ACR/EULAR Antiphospholipid Syndrome Classification Criteria”
by Lucas Jacobs, Nader Wauters, Yahya Lablad, Johann Morelle and Maxime Taghavi
Antibodies 2024, 13(1), 21; https://doi.org/10.3390/antib13010021
Available online: https://www.mdpi.com/2073-4468/13/1/21

2. “Immunogenicity and Loss of Effectiveness of Biologic Therapy for Inflammatory Bowel Disease Patients Due to Anti-Drug Antibody Development”
by Tsvetelina Velikova, Metodija Sekulovski and Monika Peshevska-Sekulovska
Antibodies 2024, 13(1), 16; https://doi.org/10.3390/antib13010016
Available online: https://www.mdpi.com/2073-4468/13/1/16

3. “Adverse Events of PD-1, PD-L1, CTLA-4, and LAG-3 Immune Checkpoint Inhibitors: An Analysis of the FDA Adverse Events Database”
by Connor Frey and Mahyar Etminan
Antibodies 2024, 13(3), 59; https://doi.org/10.3390/antib13030059
Available online: https://www.mdpi.com/2073-4468/13/3/59

4. “Antiphospholipid Antibodies Associated with Native Arteriovenous Fistula Complications in Hemodialysis Patients: A Comprehensive Review of the Literature”
by Maxime Taghavi, Abla Jabrane, Lucas Jacobs, Maria Do Carmo Filomena Mesquita, Anne Demulder and Joëlle Nortier
Antibodies 2024, 13(1), 1; https://doi.org/10.3390/antib13010001
Available online: https://www.mdpi.com/2073-4468/13/1/1

5. “Myelin Oligodendrocyte Glycoprotein-Antibody Associated Disease: An Updated Review of the Clinical Spectrum, Pathogenetic Mechanisms and Therapeutic Management”
by Panagiotis Gklinos and Ruth Dobson
Antibodies 2024, 13(2), 43; https://doi.org/10.3390/antib13020043
Available online: https://www.mdpi.com/2073-4468/13/2/43

6. “A Narrative Review of the State of the Art of CCR4-Based Therapies in Cutaneous T-Cell Lymphomas: Focus on Mogamulizumab and Future Treatments”
by Corrado Zengarini, Alba Guglielmo, Martina Mussi, Giovanna Motta, Claudio Agostinelli, Elena Sabattini, Bianca Maria Piraccini and Alessandro Pileri
Antibodies 2024, 13(2), 32; https://doi.org/10.3390/antib13020032
Available online: https://www.mdpi.com/2073-4468/13/2/32

7. “Therapeutic Advances in Psoriasis: From Biologics to Emerging Oral Small Molecules”
by Francesco Ferrara, Chiara Verduci, Emanuela Laconi, Andrea Mangione, Chiara Dondi, Marta Del Vecchio, Veronica Carlevatti, Andrea Zovi, Maurizio Capuozzo and Roberto Langella
Antibodies 2024, 13(3), 76; https://doi.org/10.3390/antib13030076
Available online: https://www.mdpi.com/2073-4468/13/3/76

8. “Unveiling GFAP Astrocytopathy: Insights from Case Studies and a Comprehensive Review of the Literature”
by Panagiotis Gklinos, Fotios Athanasopoulos, Vagia Giatrakou, Nikolaos-Achilleas Arkoudis, Dorothea Pournara, Eirini Giagkou, Argyro Tountopoulou, Sofia Vassilopoulou and Dimos-Dimitrios Mitsikostas
Antibodies 2024, 13(4), 79; https://doi.org/10.3390/antib13040079
Available online: https://www.mdpi.com/2073-4468/13/4/79

9. “A Comparison of Natural and Therapeutic Anti-IgE Antibodies”
by Monique Vogel and Paul Engeroff
Antibodies 2024, 13(3), 58; https://doi.org/10.3390/antib13030058
Available online: https://www.mdpi.com/2073-4468/13/3/58

10. “TLR2 and TLR9 Blockade Using Specific Intrabodies Inhibits Inflammation-Mediated Pancreatic Cancer Cell Growth”
by Amrendra K. Ajay, Martin Gasser, Li-Li Hsiao, Thomas Böldicke and Ana Maria Waaga-Gasser
Antibodies 2024, 13(1), 11; https://doi.org/10.3390/antib13010011
Available online: https://www.mdpi.com/2073-4468/13/1/11